This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Gastrointestinal Stromal Tumours: Correlation of Modified NIH Risk Stratification with Diffusion-weighted MR Imaging as an Imaging Biomarker
Conclusion Except tumour size and necrosis, conventional MR imaging findings did not correlate with the risk grade. However, the ADC value can be used as an imaging biomarker to assess the risk grade of GISTs, regardless of tumour size.
Source: European Journal of Radiology - November 9, 2014 Category: Radiology Source Type: research

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib
Conclusions Imatinib in locally advanced GIST is feasible and enables a high complete resection rate without tumour rupture. The combination of imatinib and surgery in patients with locally advanced GIST seems to improve PFS and OS.
Source: European Journal of Surgical Oncology (EJSO) - November 20, 2014 Category: Surgery Source Type: research

An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild type gastrointestinal stromal tumours
ConclusionsAll five antibodies failed, individually or collectively, to represent highly sensitive and highly specific markers of wild type GIST. However, while HER2 has been excluded as a therapeutic biomarker, both EGFR and IGF1R are expressed by some wild type GISTs and are therefore potential therapeutic targets.This article is protected by copyright. All rights reserved.
Source: Histopathology - February 1, 2015 Category: Pathology Authors: Newton ACS Wong, Jenny Wingate, Elise Gradhand Tags: Original Article Source Type: research

An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild‐type gastrointestinal stromal tumours
ConclusionsAll five antibodies failed, individually or collectively, to represent highly sensitive and highly specific markers for wild‐type GIST. However, whereas HER2 has been excluded as a therapeutic biomarker, both EGFR and IGF1R are expressed by some wild‐type GISTs and are therefore potential therapeutic targets.
Source: Histopathology - March 17, 2015 Category: Pathology Authors: Newton A C S Wong, Jenny Wingate, Elise Gradhand Tags: Original Article Source Type: research

miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours
This study aimed at evaluating the miR-221 and miR-222 expression profiles in different GIST subtypes and the functional role of these miRNAs. Expression of miR-221 and miR-222 was analysed in six KIT exon 9 and three KIT exon 11 mutated and nine wildtype GISTs by qPCR.
Source: Molecular Oncology - April 9, 2015 Category: Cancer & Oncology Authors: Michaela Angelika Ihle, Marcel Trautmann, Helen Kuenstlinger, Sebastian Huss, Carina Heydt, Jana Fassunke, Eva Wardelmann, Sebastian Bauer, Hans-Ulrich Schildhaus, Reinhard Buettner, Sabine Merkelbach-Bruse Source Type: research

Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours
In conclusion, regorafenib presents a valuable new tool in the treatment of patients with advanced GISTs following the failure of imatinib and sunitinib.
Source: Drugs - May 22, 2015 Category: Drugs & Pharmacology Source Type: research

Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for palliative treatment of malignant ascites from gastrointestinal stromal tumours.
Authors: Ong E, Diven C, Abrams A, Lee E, Mahadevan D PMID: 23413766 [PubMed - indexed for MEDLINE]
Source: Journal of Palliative Care - June 3, 2015 Category: Palliative Care Tags: J Palliat Care Source Type: research

Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours
This study suggests RT-PCR is more sensitive than conventional PCR for the detection of c-KIT mutations in canine GISTs.
Source: The Veterinary Journal - November 4, 2015 Category: Veterinary Research Source Type: research

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Conclusions Epidemiology of GIST demonstrates some consistent features across geographical regions. Whether the reported extreme differences in incidence reflect real variation in population risk warrants further investigation.
Source: Cancer Epidemiology - November 25, 2015 Category: Cancer & Oncology Source Type: research

The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15
In conclusion, our findings indicate the potential of PBOX-15 to improve the apoptotic response of IM in GIST cells and provide a more effective treatment option for GIST patients.
Source: Investigational New Drugs - February 17, 2016 Category: Drugs & Pharmacology Source Type: research

Large gastrointestinal stromal tumours of the stomach: Is laparoscopy reasonable?
Conclusions: LR for large GISTs is safe and technically feasible and does not negatively influence the oncologic course. Prospective randomised trials should be performed before using this approach in routine surgical care.
Source: Journal of Minimal Access Surgery - March 11, 2016 Category: Surgery Authors: Beatrice Ulloa SeverinoDavid FuksPanagiotis LainasAntoine BlainPierre ValidireJean-Marc FerrazThierry PerniceniBrice Gayet Source Type: research

Prognosis and management of adult Wild Type GastroIntestinal Stromal Tumours (GISTs): A pooled analysis and review of literature
A pooled review was performed to determine survival in adult WT GIST (Wild Type GastroIntestinal Stromal Tumours) and compare the same with pediatric WT GISTs. Electronic databases were searched using the terms “Wild type” AND “GIST”. Eighty-two adult patients from 14 studies were included in the pooled analysis. Cumulative survival was greater than 50% in both age groups, hence medial survival could not be computed. Mean survival in adults was 15.7 years ± 0.78 and in children was 18.8 years ± 1.3 (p = 0.241).
Source: Surgical Oncology - May 9, 2016 Category: Surgery Authors: N.R. Bhatt, D. Collins, P. Crotty, P.F. Ridgway Source Type: research

Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours
Conclusion Although data from randomised clinical trials on the clinical impact of sunitinib TDM are lacking, our findings support implementation of sunitinib TDM in clinical practice. For rare cancers with well-defined exposure–response relationships, modelling and simulation might allow the optimisation of dosing strategies when clinical trials cannot be performed due to low number of patients.
Source: Cancer Chemotherapy and Pharmacology - June 12, 2016 Category: Cancer & Oncology Source Type: research

The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumours
This study aimed to identify risk factors for developing additional malignancies in patients diagnosed with GIST and evaluate the impact on survival. Individuals diagnosed with GIST from 2001‐2009 were identified from the SEER database. Logistic regression was used to identify predictors of additional malignancies and Cox‐proportional hazards regression used to identify predictors of survival. In the study period, 1705 cases of GIST were identified, with 181 (10.6%) patients developing additional malignancies. Colorectal cancer was the most common cancer developing within 6 months of GIST diagnosis (30%). The median ti...
Source: International Journal of Cancer - June 13, 2016 Category: Cancer & Oncology Authors: Myles J. Smith, Henry G. Smith, Alyson L. Mahar, Calvin Law, Yoo‐Joung Ko Tags: Short Report Source Type: research

Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome
Abstract DNA repair pathways play an essential role in cancer susceptibility by maintaining genomic integrity. This led us to investigate the influence of polymorphisms in the genes coding repair pathway enzymes on gastrointestinal stromal tumours (GIST) susceptibility, tumour characteristics and clinical outcome. We investigated a panel of 20 polymorphisms in 11 genes in 81 cases and 147 controls. The XPD rs13181 wild-type allele and hOGG1 rs1052133 and XPF rs1800067 minor alleles were significantly associated with disease susceptibility. XPA rs1800975 and rs2808668 were associated with tumour size ( P  = 0.018), metas...
Source: Tumor Biology - July 26, 2016 Category: Cancer & Oncology Source Type: research